January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Committee members also weighed a proposal to streamline the dosing schedule for COVID-19 vaccines by turning them into annual shots
Additional protection against symptomatic infection provided for people who had previously received monovalent vaccine doses
Pfizer-BioNTech bivalent vaccine under investigation; Trial evaluating HIV prevention vaccine discontinued; Early detection sepsis test cleared; Trial results for RSV-associated disease vaccine; Combo Tx for HCC recurrence shows promise.
The decision to discontinue the study was made based on an analysis from an independent data and safety monitoring board.
The preliminary safety signal was identified by the CDC’s Vaccine Safety Datalink.
Vaccine hesitancy varied considerably; 12.1% of vaccinated individuals hesitant about booster doses
The approval was based on a re-analysis of data from on observational study of Tdap vaccine effectiveness in the US.
The 20vPnC vaccine consists of capsular polysaccharide conjugates for the 13 serotypes included in Prevnar 13, along with 7 additional serotypes that cause invasive pneumococcal disease.
Minor adverse events seen in 48.6 percent of patients, most often arm soreness and/or fatigue